Pharmaceutical Control of the
Human Microbiome

Symberix Scientist Presents at Immuno-Oncology Conference

September 2016

Staff Scientist Bret Wallace, Ph.D. presented at the Microbiome in Immuno-Oncology Conference, hosted by Cambridge HealthTech Institute, on September 25, 2017, in Boston, MA. The presentation titled, “Targeting Microbial β-Glucuronidases with Symbiotic Drugs to Improve Cancer Therapy,” described new bacterial drug targets in the human gut microbiome that can be exploited as part of the GUSome platform to improve cancer therapy outcomes. The conference featured both the scientific and clinical progress being made to discover and develop microbiome derived biomarkers, drug targets, and biomarkers as potential treatments for cancer.

To learn more, click here:http://www.discoveryontarget.com/discoveryontarget_homepage.aspx

 


Back to News